Advertisement
Home »

Lifileucel Induces Durable Response in Heavily Pretreated Mucosal Melanoma

Oct 26, 2023

REFERENCES & ADDITIONAL READING

D’Angelo SP, Larkin J, Sosman JA, et al. J Clin Oncol. 2017;35(2):226-35. DOI: 10.1200/JCO.2016.67.9258

 

Hamid O, Robert C, Ribas A, et al. Br J Cancer. 2018;119:670-674. DOI: 10.1038/s41416-018-0207-6

 

Chesney J, Lewis KD, Kluger H, et al. J Immunother Cancer. 2022;10(12):e005755. DOI: 10.1136/jitc-2022-005755

 

Grigoleit G-U, Kluger H, Thomas S, et al. Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study. Abstract 1086MO, ESMO 2023, 20-24 October, Madrid, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement